PT1070253E - Utilização de receptores hroralfa para o rastreio de substâncias úteis para o tratamento de aterosclerose - Google Patents

Utilização de receptores hroralfa para o rastreio de substâncias úteis para o tratamento de aterosclerose Download PDF

Info

Publication number
PT1070253E
PT1070253E PT99916886T PT99916886T PT1070253E PT 1070253 E PT1070253 E PT 1070253E PT 99916886 T PT99916886 T PT 99916886T PT 99916886 T PT99916886 T PT 99916886T PT 1070253 E PT1070253 E PT 1070253E
Authority
PT
Portugal
Prior art keywords
receptors
hroralpha
atherosclerosis
treatment
screening
Prior art date
Application number
PT99916886T
Other languages
English (en)
Inventor
Eric Raspe
Yves Bonhomme
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PT1070253E publication Critical patent/PT1070253E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT99916886T 1998-03-20 1999-03-24 Utilização de receptores hroralfa para o rastreio de substâncias úteis para o tratamento de aterosclerose PT1070253E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9803475A FR2776388B1 (fr) 1998-03-20 1998-03-20 Utilisation de recepteurs de la famille ror pour le criblage de substances utiles pour le traitement de l'atherosclerose
PCT/EP1999/002001 WO1999050660A1 (en) 1998-03-20 1999-03-24 Use of ror receptors for screening substances useful for the treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
PT1070253E true PT1070253E (pt) 2008-06-17

Family

ID=9524312

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99916886T PT1070253E (pt) 1998-03-20 1999-03-24 Utilização de receptores hroralfa para o rastreio de substâncias úteis para o tratamento de aterosclerose

Country Status (13)

Country Link
US (1) US6998254B1 (pt)
EP (1) EP1070253B1 (pt)
JP (1) JP4520039B2 (pt)
AT (1) ATE388399T1 (pt)
AU (1) AU752062B2 (pt)
CA (1) CA2326141C (pt)
DE (1) DE69938297T2 (pt)
DK (1) DK1070253T3 (pt)
ES (1) ES2303374T3 (pt)
FR (1) FR2776388B1 (pt)
NZ (1) NZ507761A (pt)
PT (1) PT1070253E (pt)
WO (1) WO1999050660A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924057D0 (en) * 1999-10-11 1999-12-15 Novartis Ag Organic compounds
HUP0300099A3 (en) * 2000-03-03 2004-10-28 Smithkline Beecham Biolog Vaccine for the treatment of artherosclerosis
FR2813315B1 (fr) * 2000-08-23 2002-10-18 Genfit S A Procede d'identification de substances utiles pour le traitement de l'inflammation mettant en oeuvre l'element de reponse du recepteur ror du gene ikbalpha
AU2002321018A1 (en) * 2001-05-07 2003-01-08 Centre National De La Recherche Scientifique Fragments of the retinoic acid-related orphan receptor (ror) comprising the lig and binding domain (lbd), crystal structure of the lbd of ror-beta and their applications
EP1501867A1 (en) * 2002-04-29 2005-02-02 Novartis AG Crystal structure of the ligand binding domain of the retinoic acid-related orphan receptor alpha (ror-alpha)
GB0306185D0 (en) * 2003-03-19 2003-04-23 Astrazeneca Ab Molecules
EP2909189B8 (en) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Heteroaryl linked quinolinyl modulators of ror-gamma-t
ME02794B (me) 2012-10-16 2018-01-20 Janssen Pharmaceutica Nv Metilen vezani hinolinil modulatori ror-gama-t
JP6251277B2 (ja) 2012-10-16 2017-12-20 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲ−ガンマ−ｔのフェニル結合キノリニルモジュレーター
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
EP3083561B1 (en) * 2013-10-15 2018-12-05 Janssen Pharmaceutica NV Heteroaryl linked quinolinyl modulators of roryt
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9346782B2 (en) 2013-10-15 2016-05-24 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
CN111088369B (zh) * 2020-01-17 2022-11-15 天津奥群牧业有限公司 一种绵羊rora基因插入/缺失多态性的检测方法、引物对和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721096A (en) * 1991-01-24 1998-02-24 Children's Medical Center Corporation Methods of screening for compounds with ability to alter apolipoprotein AI gene expression
EP0753147A1 (en) * 1994-03-30 1997-01-15 Novartis AG Screening method using the rzr receptor family
JP3981162B2 (ja) * 1994-07-18 2007-09-26 旭硝子株式会社 ポリエーテルの製造方法
US5968770A (en) * 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target

Also Published As

Publication number Publication date
JP2004500539A (ja) 2004-01-08
AU752062B2 (en) 2002-09-05
ATE388399T1 (de) 2008-03-15
CA2326141C (en) 2011-04-26
US6998254B1 (en) 2006-02-14
DK1070253T3 (da) 2008-06-23
NZ507761A (en) 2002-10-25
FR2776388B1 (fr) 2006-04-28
JP4520039B2 (ja) 2010-08-04
AU3521599A (en) 1999-10-18
EP1070253A1 (en) 2001-01-24
FR2776388A1 (fr) 1999-09-24
WO1999050660A1 (en) 1999-10-07
ES2303374T3 (es) 2008-08-01
CA2326141A1 (en) 1999-10-07
EP1070253B1 (en) 2008-03-05
DE69938297T2 (de) 2009-03-19
DE69938297D1 (de) 2008-04-17

Similar Documents

Publication Publication Date Title
PT1070253E (pt) Utilização de receptores hroralfa para o rastreio de substâncias úteis para o tratamento de aterosclerose
DE69320936D1 (de) In Wasser abbaubares Vlies
DE69700109D1 (de) Verwendung eines Extrakts mindestens einer Iridacea bei der Behandlung von Falten
DE69016634D1 (de) Inverse Multiplexer- und Demultiplexerverfahren.
BR9005636A (pt) Fibras celulosicas reticuladas,individualizadas
FI952754A (fi) Menetelmä luonnonkuituja kuten puukuituja sisältävien kuitukankaiden valmistamiseksi ja mentelmällä valmistettu kuitukangas
IT1229219B (it) Composizione acquosa gelificabile e suo uso nel recupero assistito del petrolio.
BR9913751B1 (pt) uso de uma composiÇço para proteÇço do tecido, e, mÉtodo de tratar tecido para aperfeiÇoar a sua estabilidade dimensional.
FR2721811B1 (fr) Fauteuil de relaxation
DE69712578D1 (de) Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase
DE69702862D1 (de) Verwendung von sulfatierten polysacchariden zur behandlung einer chronischer verletzung
GB2360045B (en) A method of securing a framed panel
SE9504209D0 (sv) Mjukt, bulkigt, absorberande papper innehållande kemitermomekanisk massa
FR2653354B1 (fr) Equipement de filtration autonome et portable.
DE69125175D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten bei der behandlung von atheromen
ES2061024T3 (es) Uso terapeutico de antagonistas de receptores de 5-ht3.
DE3668644D1 (de) Vorrichtung zum kontinuierlichen auslaugen von verfilztem, faserigem gut, insbesondere von zerkleinertem zuckerrohr.
FI955789A (fi) Vedetön itse-emulgoituva kemiallinen pehmennyskoostumus, joka on käyttökelpoinen kuitumaisissa selluloosamateriaaleissa
LV11542A (lv) Aizvietoti 1,3,9,11-tetraoksa-4,5,7,8-tetraazaundekadien-4,7-dioksidi- 5,7 ,to iegusana un pielietosana
DE59807902D1 (de) Lösung von tetramethylammoniumhydroxid in wasser, verfahren zur herstellung der lösung und deren verwendung
ES2196802T3 (es) Lactatos de citronelilo y/o de dihidrocitronelilo, su preparacion y su utilizacion.
EA200100336A1 (ru) Ключевые гены c.albicans и способ скрининга противогрибковых веществ с использованием упомянутых генов
DE69714031D1 (de) Nachweis von änderungen des humanen h2-rezeptoren
ES1030915Y (es) Dispositivo para evitar la falsificacion en tejidos.
ITMI910365A1 (it) Rivestimento drenante adatto particolarmente alle opere pubbliche, sua composizione e suo procedimento di realizzazione